COPD exacerbations. causes, prevention, and treatment

Medical Clinics of North America

Volumn 96, Issue 4, 2012, Pages 789-809

  Mackay, Alex J ^a   Hurst, John R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bacteria; Chronic obstructive pulmonary disease; Exacerbation; Respiratory viruses

Indexed keywords

2 METHYLHISTAMINE; AMANTADINE; AMINOPENICILLIN; AZITHROMYCIN; BACTERIUM LYSATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARBOCISTEINE; CORTICOSTEROID; DEXAMETHASONE; DNA 16S; ERYTHROMYCIN; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROFLUMILAST; SALMETEROL; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA; ZANAMIVIR;

ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHOPNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMMON COLD; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FUNCTIONAL STATUS; GAS POISONING; GENE SEQUENCE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HEADACHE; HOSPICE CARE; HOSPITALIZATION; HUMAN; HYPERCAPNIA; HYPERGLYCEMIA; HYPOXEMIA; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; LUNG EMBOLISM; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NAUSEA; NEBULIZER; NONINVASIVE VENTILATION; OXYGEN THERAPY; PALLIATIVE THERAPY; PARAINFLUENZA VIRUS INFECTION; PATIENT EDUCATION; PEAK EXPIRATORY FLOW; PHENOTYPE; PNEUMOCOCCAL INFECTION; PNEUMONIA; POLYMERASE CHAIN REACTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY REHABILITATION; RESPIRATORY DRIVE; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS INFECTION; SEASONAL VARIATION; SELF CARE; SIDE EFFECT; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

AIR POLLUTION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; DISEASE PROGRESSION; HUMANS; INFLUENZA, HUMAN; LUNG; PHENOTYPE; PICORNAVIRIDAE INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYSTEM AGENTS; RESPIRATORY THERAPY; RHINOVIRUS; VACCINATION;

EID: 84863824244     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.02.008     Document Type: Review

References (103)

1. Burden of lung disease report 2006, British Thoracic Society (BTS), Available at:, Accessed September 14, 2011. http://www.brit-thoracic.org.uk/Portals/0/Library/BTSPublications/burdeon_of_lung_disease2007.pdf, 2nd edition.
2. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138.
3. Donaldson G.C., Seemungal T.A., Bhowmik A., et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852.
4. Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001, 164(3):358-364.
5. Donaldson G.C., Hurst J.R., Smith C.J., et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010, 137(5):1091-1097.
6. Seemungal T.A., Donaldson G.C., Paul E.A., et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
7. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60(11):925-931.
8. Garcia-Aymerich J., Farrero E., Felez M.A., et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003, 58(2):100-105.
9. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003, 41:46s-53s.
10. Seemungal T., Harper-Owen R., Bhowmik A., et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(9):1618-1623.
11. Bhowmik A., Seemungal T.A., Sapsford R.J., et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000, 55(2):114-120.
12. Seemungal T.A., Donaldson G.C., Bhowmik A., et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(5):1608-1613.
13. Rohde G., Wiethege A., Borg I., et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003, 58(1):37-42.
14. Mallia P., Message S.D., Gielen V., et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011, 183(6):734-742.
15. Schneider D., Ganesan S., Comstock A.T., et al. Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182(3):332-340.
16. Di Stefano A., Maestrelli P., Roggeri A., et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994, 149(3 Pt 1):803-810.
17. Donaldson G.C., Seemungal T., Jeffries D.J., et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999, 13(4):844-849.
18. Lyon J.L., Stoddard G., Ferguson D., et al. An every other year cyclic epidemic of infants hospitalized with respiratory syncytial virus. Pediatrics 1996, 97(1):152-153.
19. Meerhoff T.J., Paget J.W., Kimpen J.L., et al. Variation of respiratory syncytial virus and the relation with meteorological factors in different winter seasons. Pediatr Infect Dis J 2009, 28(10):860-866.
20. Wilkinson T.M., Donaldson G.C., Johnston S.L., et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173(8):871-876.
21. Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999, 130(5):397-403.
22. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000, 117(5 Suppl 2):380S-385S.
23. Sethi S., Murphy T.F. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001, 14(2):336-363.
24. Murphy T.F., Brauer A.L., Sethi S., et al. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis 2007, 195(1):81-89.
25. Sethi S., Evans N., Grant B.J., et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347(7):465-471.
26. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106(2):196-204.
27. Stockley R.A., O'Brien C., Pye A., et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000, 117(6):1638-1645.
28. Miravitlles M., Marin A., Monso E., et al. Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease. Respir Res 2010, 11:58.
29. Monso E., Ruiz J., Rosell A., et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1316-1320.
30. Patel I.S., Seemungal T.A., Wilks M., et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57(9):759-764.
31. Hilty M., Burke C., Pedro H., et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5(1):e8578.
32. Erb-Downward J.R., Thompson D.L., Han M.K., et al. Analysis of the lung microbiome in the " healthy" smoker and in COPD. PLoS One 2011, 6(2):e16384.
33. Wilkinson T.M., Hurst J.R., Perera W.R., et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest 2006, 129(2):317-324.
34. Rosell A., Monso E., Soler N., et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005, 165(8):891-897.
35. Sethi S., Sethi R., Eschberger K., et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 176(4):356-361.
36. Abusriwil H., Stockley R.A. Bacterial load and exacerbations of COPD. Am J Respir Crit Care Med 2008, 177(9):1048-1049. [author reply: 1049].
37. Sajjan U.S., Jia Y., Newcomb D.C., et al. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J 2006, 20(12):2121-2123.
38. Papi A., Bellettato C.M., Braccioni F., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173(10):1114-1121.
39. Anderson H.R., Spix C., Medina S., et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997, 10(5):1064-1071.
40. Wordley J., Walters S., Ayres J.G. Short term variations in hospital admissions and mortality and particulate air pollution. Occup Environ Med 1997, 54(2):108-116.
41. Dominici F., Peng R.D., Bell M.L., et al. Fine particulate air pollution and hospital admission for cardiovascular and respiratory diseases. JAMA 2006, 295(10):1127-1134.
42. Nordenhall C., Pourazar J., Blomberg A., et al. Airway inflammation following exposure to diesel exhaust: a study of time kinetics using induced sputum. Eur Respir J 2000, 15(6):1046-1051.
43. Rudell B., Blomberg A., Helleday R., et al. Bronchoalveolar inflammation after exposure to diesel exhaust: comparison between unfiltered and particle trap filtered exhaust. Occup Environ Med 1999, 56(8):527-534.
44. Nichol K.L., Nordin J.D., Nelson D.B., et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007, 357(14):1373-1381.
45. Nichol K.L., Baken L., Wuorenma J., et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999, 159(20):2437-2442.
46. Alfageme I., Vazquez R., Reyes N., et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006, 61(3):189-195.
47. National Clinical Guideline Centre Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010, National Clinical Guideline Centre, London, Available at:, Accessed September 14, 2011. http://guidance.nice.org.uk/CG101/Guidance/pdf/English.
48. Sprenkle M.D., Niewoehner D.E., MacDonald R., et al. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD 2005, 2(1):167-175.
49. Orcel B., Delclaux B., Baud M., et al. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994, 7(3):446-452.
50. Collet J.P., Shapiro P., Ernst P., et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997, 156(6):1719-1724.
51. Soler M., Mutterlein R., Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007, 74(1):26-32.
52. Cazzola M., Rogliani P., Curradi G. Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view. Respir Med 2008, 102(3):321-327.
53. Burge P.S., Calverley P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320(7245):1297-1303.
54. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
55. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554.
56. Aaron S.D., Vandemheen K.L., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8):545-555.
57. Puhan M.A., Bachmann L.M., Kleijnen J., et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009, 7:2.
58. Rossi A., Kristufek P., Levine B.E., et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121(4):1058-1069.
59. Zhou Y., Wang X., Zeng X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006, 11(5):603-610.
60. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374(9691):685-694.
61. Seemungal T.A., Wilkinson T.M., Hurst J.R., et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178(11):1139-1147.
62. Albert R.K., Connett J., Bailey W.C., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365(8):689-698.
63. Sethi S., Jones P.W., Theron M.S., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010, 11:10.
64. Zheng J.P., Kang J., Huang S.G., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008, 371(9629):2013-2018.
65. Barnes P.J. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004, 1(3):264-268.
66. Ito K., Ito M., Elliott W.M., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005, 352(19):1967-1976.
67. Cosio B.G., Tsaprouni L., Ito K., et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004, 200(5):689-695.
68. Ito K., Lim S., Caramori G., et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A 2002, 99(13):8921-8926.
69. Marwick J.A., Caramori G., Casolari P., et al. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010, 125(5):1146-1153.
70. Marwick J.A., Caramori G., Stevenson C.S., et al. Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009, 179(7):542-548.
71. Renda T., Baraldo S., Pelaia G., et al. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31(1):62-69.
72. Armstrong J., Harbron C., Lea S., et al. Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2011, 338(3):732-740.
73. Fishman A., Martinez F., Naunheim K., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348(21):2059-2073.
74. Washko G.R., Fan V.S., Ramsey S.D., et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 177(2):164-169.
75. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980, 93(3):391-398.
76. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1(8222):681-686.
77. Garcia-Aymerich J., Monso E., Marrades R.M., et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001, 164(6):1002-1007.
78. McEvoy R.D., Pierce R.J., Hillman D., et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009, 64(7):561-566.
79. Casaburi R., ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009, 360(13):1329-1335.
80. Hurst J.R., Wedzicha J.A. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med 2009, 7:40.
81. Wilkinson T.M., Donaldson G.C., Hurst J.R., et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169(12):1298-1303.
82. Bourbeau J., Julien M., Maltais F., et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003, 163(5):585-591.
83. Casas A., Troosters T., Garcia-Aymerich J., et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006, 28(1):123-130.
84. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370(9589):786-796.
85. McCrory D.C., Brown C.D. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, 4. CD003900.
86. Global Strategy for the Diagnosis, Management and Prevention of COPD 2009, Global Initiative for Chronic Obstructive Lung Disease (GOLD), Available at:, Accessed September 14, 2011. http://www.goldcopd.org.
87. Nouira S., Marghli S., Belghith M., et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001, 358(9298):2020-2025.
88. Martinez F.J. Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4(8):647-658.
89. Anzueto A., Niederman M.S. Diagnosis and treatment of rhinovirus respiratory infections. Chest 2003, 123(5):1664-1672.
90. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999, 354(9177):456-460.
91. Niewoehner D.E., Erbland M.L., Deupree R.H., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999, 340(25):1941-1947.
92. Thompson W.H., Nielson C.P., Carvalho P., et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996, 154(2 Pt 1):407-412.
93. Maltais F., Ostinelli J., Bourbeau J., et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002, 165(5):698-703.
94. Wood-Baker R.R., Gibson P.G., Hannay M., et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, 1. CD001288.
95. McCrory D.C., Brown C., Gray R.N., et al. Management of acute exacerbations of chronic obstructive pulmonary disease. Evid Rep Technol Assess (Summ) 2000, (19):1-4.
96. Joint Formulary Committee British National Formulary 2011, British Medical Association and Royal Pharmaceutical Society, London. 61st edition.
97. Roede B.M., Bresser P., Bindels P.J., et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008, 63(11):968-973.
98. Roede B.M., Bresser P., Prins J.M., et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009, 33(2):282-288.
99. Duffy N., Walker P., Diamantea F., et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005, 60(9):713-717.
100. O'Driscoll B.R., Howard L.S., Davison A.G. BTS guideline for emergency oxygen use in adult patients. Thorax 2008, 63(Suppl 6):vi1-vi68.
101. Ram F.S., Lightowler J.V., Wedzicha J.A. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003, 1. CD004104.
102. Esteban A., Anzueto A., Frutos F., et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002, 287(3):345-355.
103. Clemens K.E., Quednau I., Klaschik E. Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study. Support Care Cancer 2009, 17(4):367-377.